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Abstract  
Sodium stibogluconate (SSG) is the first-line therapy for visceral eishmaniasis (VL) in south-eastern 
Nepal. Recent studies from the neighbouring state of Bihar, India, have shown a dramatic fall in cure 
rates with treatment failure occurring in up to 65% of VL patients treated with SSG. A prospective study 
was conducted at a tertiary-level hospital located in south-eastern Nepal from July 1999 to January 2001. 
Parasitologically proven kala-azar patients with no previous history of treatment for VL were treated with 
SSG 20 mg/kg/d for 30 d which was extended to 40 d in those with persistent positive parasitology. Of 
the 110 patients who completed SSG therapy and were assessed at 1 and 6 months, definite cure was 
achieved in 99 patients (90%) and SSG failure occurred in 11 patients (10%). Except for the presence of 
hepatomegaly and a lower platelet count there was no clinical or laboratory baseline characteristic 
associated with treatment failure. A significantly lower cure rate (76%, P= 0.03) was observed in 
patients from the district of Saptari, which borders the antimony-resistant VL areas of Bihar. The efficacy 
of SSG as a first-line treatment for VL in south-eastern Nepal was still satisfactory, except for the patients 
living closer to the antimony-resistant VL areas of India. These findings indicate that the spread of 
resistance to antimonials i already taking place in Nepal and that a policy to control further spread 
should be urgently implemented. 
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Int roduct ion 
Visceral leishmaniasis (VL) or kala-azar affects an 
estimated 500 000 persons every year worldwide, with 
50% of cases reported from Bangladesh, India, and 
Nepal (Desjeux, 2001). Visceral leishmaniasis is con- 
sidered a major health problem in Nepal and is ende- 
mic in 12 districts of the eastern and central part of the 
southern Terai region, where an estimated 6 million 
people are at risk of acquiring the disease (Ministry of 
Health, Nepal, 1999/2000). This region borders the 
northern part of the state of Bihar in India, which has 
been the epicentre of the Indian epidemic. 
In Nepal, as in most VL-endemic regions, the first- 
line treatment relies on pentavalent antimony, such as 
sodium stibogluconate (SSG), as recommended bythe 
WHO (1990). In spite of the inconvenience of pro- 
longed parenteral therapy and potential for severe ad- 
verse effects SSG is still used mainly due to its proven 
efficacy and, when generic ompounds are used, afford- 
ability (Veeken et al., 2000). However, in the state of 
Bihar in India, there has been an increasing resistance 
to SSG since the early 1980s despite agradual increase 
of the dose and duration of treatment up to the maxi- 
mum recommended dose of 20 mg/kg/d for 30 d (Sun- 
dar, 2001). In 1991-92, cure rates of 60% and 64% 
were found in 2 separate studies using this maximum 
recommended dose (Jha et al., 1992; Sundar et al., 
1995). This trend has shown a further decline and a 
recent study has reported a long-term cure rate of only 
35% (Sundar et al., 2000a). Thus, SSG has now been 
abandoned and replaced by the more expensive 
amphotericin B as the first-line therapy for VL in Bihar. 
In Nepal, data on the efficacy of SSG is poorly 
documented. There has been only 1 published study 
(Karki et al., 1998) that compared SSG 20 mg/kg/d 
given for 20 d compared with 30 d in 2 groups of 27 
patients each. The definite cure rate was found to be 
78% and 93%, respectively. 
One of the important contributing factors to the drug 
resistance in Bihar has been attributed to the use of 
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infra-therapeutic doses and/or insufficient duration of 
SSG therapy (Sundar, 2001). This phenomenon also 
exists in Nepal. Moreover, the socio-cultural similarity 
and the open border between southern Nepal nd 
northern Bihar facilitate cross-border population move- 
ments which may also play an important role in the 
spread of SSG-resistant s rains of Leishmania donovani. 
The objective of the study was to obtain the current 
status of SSG efficacy in the VL-endernic regions of 
eastern Nepal and to look for any factors associated 
with drug resistance. A policy for the control of SSG 
resistance in Nepal is discussed. 
Mater ia ls  and Methods  
Study site 
This study was conducted at the B. P. Koirala 
Institute of Health Sciences (BPKIHS), a 650-bed 
University Hospital located 2 kin from the town of 
Dharan, Sunsari district in the Eastern region of Nepal. 
The BPKIHS serves as a reference tertiary-level hospi- 
tal for the Eastern region which includes everal VL- 
endemic districts. Recruitment ofpatients took place at 
the outpatient department and the emergency room of 
BPKIHS from July 1999 to August 2000. Patients 
came directly to BPKIHS or were referred from the 
district hospitals. The Ethical Committee of BPKIHS 
approved the research protocol in May 1999. 
Inclusion and exclusion criteria 
Parasitologically proven VL cases with no history of 
previous treatment with SSG were included after ob- 
taining informed consent from the patient or his/her 
guardian. Only patients from the 3 neighbouring dis- 
tricts of Sunsari, Morang, and Saptari were included as 
follow-up would not be practically possible for patients 
coming from more remote districts. There was no other 
exclusion criteria. 
Initial evaluation 
All patients with suspected VL (history of fever t> 2 
weeks duration and clinical splenomegaly) were ad- 
mitted to the medical or paediatric ward for a complete 
examination. This included clinical evaluation, com- 
plete blood count, chemistry, blood culture, urine 
analysis, and chest radiography. HIV testing was done 
after pre-test counselling using Vironostica ®and Re- 
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combigen ®enzyme-linked immunosorbent assay tests. 
Diagnosis of VL was made by Giemsa-stained bone 
marrow aspirate or spleen aspirate (if bone marrow 
aspirate was negative). Stained smears were designated 
as 'positive' if L. donovani bodies were seen or 'nega- 
tive' if none were seen in 100 oil immersion fields. Two 
doctors read the slides independently. Parasite density 
score was determined microscopically in the Giemsa- 
stained smears by the use of a logarithmic scale ranging 
from 0 (no parasites per 100 oil immersion fields) to
+ 6 (> 100 parasites per field). For quality control, 
10% of the slides were cross-checked atthe Protozool- 
ogy Unit (Prof. Dominique Le Ray) of the Institute of 
Tropical Medicine in A twerp, Belgium. 
Treatment 
All the patients included were allocated into 2 treat- 
ment groups: Group A received the full treatment 
course in the hospital nd Group B received the first 5-  
7 d treatment in the hospital and the rest as outpatients 
at the nearest health facility to their place of residence. 
Allocation into the 2 groups was made according to 
patients' preference as random allocation was not pos- 
sible. Patients were treated with generic SSG (sodium 
antimony gluconate [SAG] from Albert David Ltd, 
Calcutta, India) 20 mg/kg/d for 30 d as recommended 
by the Nepalese National Guidelines. 
Follow-up 
Clinical assessment and parasitological examination 
for L. donovani bodies was repeated at the end of 30 d 
of SSG therapy (1-month follow-up). If L. donovani 
bodies were still present at this time, SSG was extended 
for another 10 d. If at the end of this extended period 
L. donovani bodies were still found in tissue aspirate, 
the patient was then treated with the second-line ther- 
apy amphotericin B, 0.5 mg/kg/d for 14 d. All patients 
were followed-up at 3 and 6 months for further clinical 
evaluation. Parasitological examination was repeated at 
6 months in all patients and at 3 months if relapse was 
clinically suspected (fever, spleen enlargement). The 
patients were followed-up at the BPKIHS or actively in 
their homes if they did not attend the BPKIHS on the 
fixed date. All relapse cases were treated with ampho- 
tericin B 0.5 mg/kg/d for 14 d. 
Case definitions 
We used the following definitions: VL case, patient 
with clinical signs (prolonged fever and splenomegaly) 
and positive for L. donovani bodies in tissue aspirate 
(bone marrow or spleen); initial cure, a VL case with 
absence of fever and negative parasitology at the end of 
SSG therapy; non-responder, a VL case with positive 
parasitology after 40 d of SSG therapy; definitive cure, 
a VL case with no clinical signs of relapse and negative 
parasitology at 6 months follow up; relapse case, a VL 
case with initial cure but with reappearance of clinical 
signs and positive parasitology during the 6 months 
follow-up; and SSG failure, non-responder o  relapse 
case.  
Statistical analysis 
Frequencies and cross-tabulations were used to de- 
scribe the proportions of treatment failure across base- 
line socio-demographic and medical characteristics. 
Mean and median values were used for continuous 
characteristics such as age or duration of fever. To 
study the ffect of place of stay, logistic regression was 
used to adjust for other significant socio-demographic 
and medical factors. Pearson's ){2, independent sample 
t tests, and Mann-Whitney U tests were used to test he 
statistical differences across groups, where appropriate. 
All tests were two-tailed, with a significance level of 
0.05. 
Results 
Between July 1999 and August 2000, 120 VL pa- 
tients were included in the study and started on SSG 
therapy. Four patients (3.3%) died during the course of 
treatment: 2 from cardiotoxicity (electrocardiographic- 
proven arrhythmia), 1 from septic shock and 1 patient 
with underlying psychiatric illness who committed sui- 
cide during his hospital stay. Two other patients devel- 
oped evidence of cardiotoxicity during SSG treatment 
and were switched to amphotericin B. The total inci- 
dence of cardiotoxicity due to SSG was thus 3.3%. 
Of the 114 patients who completed 30 d SSG ther- 
apy, 103 had a negative parasitology. Eleven remained 
parasitologically positive and required extension of the 
SSG therapy to 40 d. Of these 11, only 1 became 
parasitologically negative and 10 remained positive 
after 40 d. Thus, at completion of treatment there were 
104 initial cures and 10 non-responders. Four patients 
who had shown initial cure were lost to follow-up at 6 
months. Of the 100 patients analysed at 6 months 
follow-up, 1 had a positive parasitology (relapse) and 
99 remained parasitologically negative (definite cure). 
The 10 patients with unknown status of resistance to 
SSG (death during treatment (4), treatment changed 
to amphotericin B (2), and lost to follow-up (4)) were 
excluded from further analysis. Of the remaining 110 
patients, SSG failure (non-responders or relapse) was 
seen in 10% (11/110) and definite cure was achieved 
in 90% (99/110). Table 1 compares baseline socio- 
demographic characteristics, clinical signs and labora- 
tory values in the 110 patients followed-up at 6 
months. 
All the patients were negative to HIV testing. A total 
of 84 (76%) received the full treatment as in-patients 
(group A) and 26 (24%) received the initial SSG 
treatment (5-7 d) as in-patients and the rest as out- 
patients in the peripheral health facilities (group B). 
Treatment failure was only significantly associated 
with the place of stay, the presence of hepatomegaly, 
and a lower platelet count (Table 2). Treatment failure 
occurred in 24% of patients coming from the district of 
Saptari compared with only 5% for the district of 
Sunsari and 6% for the district of Morang (P = 0.03). 
Patients coming from Saptari were more frequently 
men (80% vs. 53%, P= 0.02), more frequently had a 
positive blood culture at the time of diagnosis (20% vs. 
5%, P = 0.01), and had more parasites n bone marrow 
examination (57% with +++ to +++++ vs. 31% with + 
to ++, P = 0.03). However, patients coming from Sap- 
tari district did not show any other significant differ- 
ence in disease severity such as duration of fever, spleen 
size, and haemoglobin count when compared with 
patients from the other 2 districts (data not shown). In 
logistic regression analysis, taking into account the 
effect of gender, positive blood culture and degree of 
parasite infestation i  the bone marrow, treatment fail- 
ure was still more frequent for patients coming from 
Saptari (OR = 6.8, 95% CI 1.3-37.1). 
Discuss ion 
In this study, we found that the current efficacy of 
SSG in the treatment of VL remains atisfactory in the 
eastern part of the VL-endemic area of Nepal where 
90% of patients who completed their treatment and 6- 
month follow-up showed a definite cure. Except for the 
presence of hepatomegaly and a lower platelet count, 
we did not find any clinical or laboratory findings 
associated with resistance to SSG, as also reported by 
Sundar et aL (2000a) in India. Co-infection with HIV, 
an important cause of treatment failure, was not found 
in this study. 
However, a significantly ower cure rate of 76% was 
found in patients coming from the district of Saptari, 
situated in the western extremity of the study area and 
closer to the northern districts of the Indian state of 
Bihar (Figure) where sistance to SSG is at its highest 
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Table 1. Compar ison of  basel ine soe io-demographic ,  cl inical, and laboratory values in 110 visceral  
le ishmanias is  patients treated with sod ium st ibogluconate in south-eastern Nepal  with definite cure or 
t reatment  failure at six months  fol low-up, July 1999-August 2000 
Treatment 
Overall Definite cure failure 
(n = 110) (n = 99) (n = 11) 
Mean (SD) Mean Mean pa 
Socio-demographic characteristics 
Age (years) 23.8 (13.9) 24.1 21.5 
Clinical signs 
Duration of fever (weeks) 7.6 (7.0) 7.6 7.1 
Temperature (°F) 102.3 (1.4) 102.3 102.5 
Spleen size (cm) 5.7 (3.5) 5.6 6.5 
Laboratory test results 
Haemoglobin (g/dL) 8.9 (1.8) 8.9 8.4 
White blood cells (/mm 3) 4030 (1310) 3990 4360 
Platelets ( /mm 3) 148 900 (73 700) 152 400 117 300 
Creatinine (mg/dL) 0.67 (0.24) 0.68 0.61 
DAT end titre (1 missing value) b 819 200 (-) 819 200 3 276 800 
0.55 
0.82 
0.70 
0.42 
0.39 
0.39 
0.02 
0.37 
0.37 
aIndependent samples t test. 
bMedian values and Mann-Whitney U test (DAT end titres were not normally distributed). 
Table 2. Relat ionships between t reatment  failure assessed at 6 months  
fol low-up and basel ine soc io-demographic  and cl inical characterist ics of  
110 visceral le ishmanias is  patients treated with sod ium st iboglueonate in 
south-eastern Nepal,  July 1999-August 2000 
Overall Treatment failure 
(n = 110) (n= 11) 
n (%) n (%) pa 
Socio-demographic characteristics 
Gender 0.33 
Male 65 (59.1) 5 (7.7) 
Female 45 (40.9) 6 (13.3) 
Place of stay 0.03 
Sunsari 38 (34.5) 2 (5.3) 
Saptari 25 (22.7) 6 (24.0) 
Morang 47 (42.7) 3 (6.4) 
Occupation 0.24 
Farmer 26 (23.6) 2 (7.7) 
Housewife 22 (20.0) 1 (4.5) 
Student 50 (45.5) 8 (16.0) 
Other 12 (10.9) 0 
Symptoms and clinical signs 
Weakness 34 (30.9) 5 (14.7) 0.27 
Weight loss 76 (69.1) 7 (9.2) 0.68 
Cough 11 (10.0) 2 (18.2) 0.34 
Abdominal pain 23 (20.9) 3 (13.0) 0.58 
Vomiting 5 (4.5) 1 (20.0) 0.45 
Skin darkening 31 (28.2) 4 (12.9) 0.53 
Lymph nodes 5 (4.5) 0 0.45 
Hepatomegaly 76 (69.1) 11 (14.5) 0.02 
Laboratory test results 
BM intensity (15 missing values) 0.20 
+ to ++ 60 (63.2) 5 (8.3) 
+++ to +++++ 35 (36.8) 6 (17.1) 
Positive blood culture 9 (8.2) 1 (11.1) 0.91 
Positive malaria smear 2 (1.8) 0 0.63 
Associated tuberculosis 3 (2.7) 1 (33.3) 0.17 
Type of care 0.65 
In-patient (Group A) 84 (76.4) 9 (10.7) 
Outpatient (Group B) 26 (23.6) 2 (7.7) 
~Pearson's X 2 test. 
(Sundar et al., 2001). This decreased cure rate ob- 
served in patients from Saptari is not likely to be due to 
differences in patients' characteristics or disease sever- 
ity. Our results suggest hat it is most likely that the 
decreased response to treatment observed in Saptari 
district is due to resistant strains of L. donovani as 
recently demonstrated in Bihar (Lira et al., 1999). The 
resurgence of VL in Nepal st rted in the early 1980s, a 
decade after the epidemic began in Bihar, which could 
explain the current observed ifference of SSG efficacy 
between the 2 countries. The increased failure rate in 
patients from Nepalese districts neighbouring Bihar 
strongly suggests that the spread of SSG resistance is
taking place in Nepal and it may follow a similar course 
to that in Bihar if no immediate measures are taken. 
The intense cross-border population movement be- 
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Figure. Map showing the 12 visceral leishmaniasis-endemic districts in outh-eastern Nepal andthe antimony resistance area in the 
state of Bihar, India, 1999. BPIZdHS, B. P. Koirala Institute of Health Sciences. 
tween the state of Bihar and the Tera'i plain of Nepal 
could facilitate the spread of the resistant parasites. 
Moreover, drug misuse, a well-recognized risk factor 
for the development of resistant parasites (Bryceson 
et al., 1985), is also common but poorly documented in 
Nepal: inadequate dosage and/or duration of treatment 
of SSG is often prescribed in Nepal, mostly by poorly 
qualified practitioners. In Bihar, Sundar et al. (1994) 
showed that only 26% of the 312 patients previously 
treated with SSG and presenting with a refractory 
disease had been treated according to the WHO (1996) 
guidelines. 
The current free provision of VL drugs in Nepal to 
all hospitals located in the endemic region, as part of 
the National Kala-azar Control Program of the Nepa- 
lese Ministry of Health, may be a factor promoting 
adequate drug use. This may relieve economic pressure 
on patients to prematurely interrupt treatment but does 
not solve the constraints of transport and costs of 
hospitalization. Most VL patients belong to the lowest 
socio-economic class and have very limited capacity to 
pay for the cost of treating the disease (Desjeux, 1996). 
Moreover, the vast majority of VL patients admitted to 
public hospitals in Nepal receive only the initial few 
days of SSG until clinical improvement as in-patients 
and their treatment is completed as outpatients in 
peripheral health facilities. Considering the long daily 
walking time to reach health facilities, the painful i.m. 
iniections and the other priorities of daily life, this 
strategy may lead to inadequate adherence to treat- 
ment, subsequently decreasing treatment efficiency and 
promoting the selection of resistant parasites. In our 
study, we did not find any significant difference in the 
outcome of patients between those receiving the full 
treatment as in-patients and those treated mostly as
outpatients. However thisstudy design had limitations, 
as we were unable to randomize the patients groups. 
As suggested by Bryceson (2001), a policy to prevent 
and control the spread of SSG resistance should be 
implemented in VL-endemic areas like Nepal. Such a 
policy should include the reinforcement of current 
activities aiming to decrease overall disease transmis- 
sion, measures to prevent drug misuse and implemen- 
tation, after evaluation, of combination therapies. 
The tools available for the control of anthroponotic 
VL have been recently reviewed by Boelaert et al. 
(2000). Vector control through insecticide spraying, in 
association with early case detection and treatment, is
an effective way to reduce transmission of the disease 
(Saxena et al., 1996), and thus also transmission of 
drug-resistant s rains. This requires strong political 
commitment and is costly. The use of impregnated 
bednets has the potential to protect healthy people 
against VL (Bern et al., 2000), and to impede untreated 
patients to disseminate the parasite through sandfiy 
bites. 
Measures to prevent SSG misuse in Nepal could 
include the widespread implementation f test-treat- 
ment algorithms, directly observed therapy for out- 
patients' care, education of practitioners from both 
public and private sectors to prescribe adequate treat- 
ment schedules, adequate supply of reliable generic 
SSG with proven efficacy and safety profile to health 
facilities in the endemic areas, and the patients' access 
to free or very low-cost drugs. 
The use of combination therapy for VL could be 
an appealing approach for treating patients in drug- 
resistant areas, protecting each component of the com- 
bination against selection of resistant mutants and 
using drugs at lower and thus safer total doses. In the 
case of malaria, a control of mefloquine resistance has 
been obtained within a few years of systematic use of 
the artesunate-mefloquine combination in western 
Thailand (Nosten et al., 2000). It is currently unclear if 
a similar strategy for VL would be successful but such 
an approach should be considered in areas, such as 
Nepal, where resistance to SSG is increasing. Combi- 
nations of SSG and paromomycin have shown to be 
efficient and safe in India (Thakur et al., 2000), Sudan 
(Seaman et al., 1993), and Kenya (Chunge et al., 1990) 
but paramomycin has yet to be registered for VL treat- 
ment and its future production and cost remain un- 
clear. Other possible combinations could include in 
future trials conventional or liposomal amphotericin B 
as well as miltefosine, an oral drug showed to be very 
efficient in India when used alone for 4 weeks (Jha et 
al., 1999; Sundar et al., 2000b). Miltefosine was regis- 
tered for the treatment of VL in India in 2002 and a 
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phase IV trial will take place in India and Nepal in the 
coming year. However, because of the long half-life of 
miltefosine and the long duration of treatment, one 
might fear that L. donovani will rapidly develop resis- 
tance to this drug if it is used alone. 
Regular monitoring of SSG susceptibility in Nepal 
should be an important component of this policy. It 
should be performed preferably in vitro using the amas- 
tigote-macrophage model, which evaluate the resis- 
tance of L. donovani isolates to antimonials (Croft, 
2001). 
The HIV seroprevalence in the general population in 
Nepal is currently around 0.3% but risk factors for an 
increasing prevalence are present (Furber tal., 2002). 
Monitoring and fighting the progression of HIV disease 
is very important in this region considering the much 
higher risk of treatment failure in HIV-VL co-infected 
patients treated with SSG or with any other anti-VL 
drugs (Lopez-Velez et aL, 1998). 
In conclusion, we showed that the efficacy of SSG to 
treat VL in eastern Nepal remains satisfactory overall 
but that areas of lower response to SSG exist in this 
region. Considering the lower price of SSG (in its 
generic form) and the higher cost and/or lack of avail- 
ability of present alternative therapies, it is necessary 
that current efforts in Nepal focus on limiting the 
spread of resistance to SSG. 
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